GSK CEO Emma Walmsley will step down in January, with Luke Miels taking over amidst looming US tariffs on branded pharmaceutical imports. This leadership change comes as GSK navigates critical global trade conditions, despite a recent $30 billion US investment. Miels faces the challenge of securing growth plans under new economic pressures.